Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2334
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study ; volume:7 ; number:1 ; day:02 ; month:7 ; year:2007 ; pages:1-7 ; date:12.2007
BMC infectious diseases ; 7, Heft 1 (02.7.2007), 1-7, 12.2007
- Creator
-
Riedel, Amy
- Contributor
-
Choe, Lan
Inciardi, John
Yuen, Courtney
Martin, Thomas
Guglielmo, B Joseph
SpringerLink (Online service)
- DOI
-
10.1186/1471-2334-7-70
- URN
-
urn:nbn:de:1111-2016030249811
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Riedel, Amy
- Choe, Lan
- Inciardi, John
- Yuen, Courtney
- Martin, Thomas
- Guglielmo, B Joseph
- SpringerLink (Online service)
Other Objects (12)
Antifungal Prophylaxis in the Era of Targeted Chemotherapy for Acute Myelogenous Leukemia
Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis
Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study
Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice
Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy
Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim - First Interim Analysis
Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study
Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
Chemotherapy and febrile neutropenia - diagnostic and therapeutic management
Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia
Optimization of Antifungal Prophylaxis in Haematological High-Risk Patients
Antifungal Prophylaxis in the Era of Targeted Chemotherapy for Acute Myelogenous Leukemia
Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis
Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study
Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice
Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy
Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim - First Interim Analysis
Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study
Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
Chemotherapy and febrile neutropenia - diagnostic and therapeutic management
Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia
Optimization of Antifungal Prophylaxis in Haematological High-Risk Patients
Antifungal Prophylaxis in the Era of Targeted Chemotherapy for Acute Myelogenous Leukemia
Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis
Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study
Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice
Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy
Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim - First Interim Analysis
Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study
Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
Chemotherapy and febrile neutropenia - diagnostic and therapeutic management
Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia